FDA Approval Insights: TheraSphere Y-90 Glass Microspheres in HCC

Season 5 Episode 2  ·  Apr 26, 2021, 07:06 PM

Headliner
Share
Subscribe

Riad Salem, MD, discusses the unique elements of the radioembolization technology, the data that supported the regulatory approval, and the anticipated future for TheraSphere in HCC.

Share
Subscribe
Next
Riedel and Van Tine Spotlight Sarcoma Advances and Preview Ongoing Studies
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air